Aimed Bio Inc
0009K0
Company Profile
Business description
Aimed Bio Inc is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, especially antibody-drug conjugates (ADC) and bispecific antibodies. It is a next-generation anticancer technology designed to maximize therapeutic efficacy and reduce side effects compared to existing chemotherapeutic agents by selectively delivering anticancer drugs to cancer cells via antibodies. Its product pipelines are AMB302, AMB303, AMB001, and Others.
Contact
67 Jeongui-ro
10th and 11th floors, MK Tower
Songpa-gu
Seoul
KORT: +82 262850743
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
51
Stocks News & Analysis
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
stocks
After earnings, we raise our Tesla stock Fair Value Estimate. Are shares a buy?
Solid results included strong full-self driving software uptake and positive free cash flow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,736.85 | 26.68 | 0.19% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |